Section of Orthopaedics, Department of Surgical Sciences, Uppsala University Hospital, Sweden.
Swedish Arthroplasty Register, Gothenburg, Sweden; Department of Orthopaedics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Sweden.
Acta Orthop. 2022 Feb 8;93:317-326. doi: 10.2340/17453674.2022.2044.
Concerns related to a potentially increased risk of cancer after total hip arthroplasty (THA) have frequently surfaced, especially since the novel EU medical device regulation classified cobalt as carcinogenic. We assessed the risk of cancer after THA in a nationwide cohort of patients younger than 55 years at surgery.
In this population-based longitudinal cohort study, 18,771 individuals exposed to THA were identified in the Swedish Hip Arthroplasty Registry (SHAR) and compared with 87,683 unexposed individuals who were matched by age, sex, and residence. Diagnoses, socioeconomic background, and dates of death were obtained from the Swedish Cancer Register, the National Patient Register, and Statistics Sweden. Primary outcome was the adjusted risk of any cancer after the first THA; secondary outcomes were specific cancer forms.
We found no enhanced adjusted risk of developing any cancer, either in exposed females compared with unexposed females (hazard ratio [HR] 1.1, 95% confidence interval [CI] 0.95-1.2), or in exposed males (HR 1.1, CI 0.99-1.2). When analysing specific cancers, increased adjusted risks were found for thyroid and pancreas cancer in exposed females, and for cancer of the stomach, skin melanoma, and prostate cancer in exposed males.
This study indicates that there is no statistically significant increased overall risk of cancer in young THA-exposed patients. The potentially slightly enhanced risk for specific cancers may be due to residual confounding resulting from risk factors not accounted for and merits further investigation.
全髋关节置换术(THA)后癌症风险增加的相关问题备受关注,尤其是新型欧盟医疗器械法规将钴归类为致癌物质之后。我们评估了在一个接受 THA 的 55 岁以下的全国性患者队列中发生癌症的风险。
在这项基于人群的纵向队列研究中,在瑞典髋关节置换登记处(SHAR)中确定了 18771 名接受 THA 的患者,并与 87683 名未接受 THA 的患者进行了匹配,匹配因素包括年龄、性别和居住地。诊断、社会经济背景和死亡日期均来自瑞典癌症登记处、国家患者登记处和瑞典统计局。主要结局是首次 THA 后任何癌症的调整后风险;次要结局是特定癌症类型。
我们发现,与未暴露女性相比,接受 THA 的女性(风险比 [HR] 1.1,95%置信区间 [CI] 0.95-1.2)或男性(HR 1.1,CI 0.99-1.2)并没有更高的调整后癌症发生风险。在分析特定癌症时,发现暴露于 THA 的女性甲状腺癌和胰腺癌的调整后风险增加,而暴露于 THA 的男性胃癌、皮肤黑色素瘤和前列腺癌的调整后风险也增加。
这项研究表明,在年轻的接受 THA 的患者中,总体癌症风险没有统计学上的显著增加。特定癌症的潜在风险增加可能是由于未考虑的风险因素造成的残余混杂,值得进一步研究。